DISCOVERY CHANNEL DOCUMENTARY “PAIN MATTERS” CHRONICLES THE BURDENS OF LIVING WITH CHRONIC PAIN
Loved Ones Provide Significant Support, But Many Still Struggle with Pain’s Invisibility, New Survey Finds
North Wales, Pa., November 4, 2013 – There are 100 million American adults who live with chronic pain – more than cancer, diabetes and heart disease combined. A new documentary titled “Pain Matters,” airing Nov. 16 on the Discovery Channel, explores the realities of chronic pain through the eyes of individuals who live with it, as well as the perspective from leading national experts in pain management.
The film features a range of stories of people living with chronic pain including a U.S. Navy veteran and a two-time Stanley Cup-winning hockey player. “Pain Matters” chronicles their individual challenges in managing their condition, including validation of their pain due to the difficulty in objectively measuring it and working with healthcare professionals to develop an individualized treatment plan.
"We hope that the personal stories told through ‘Pain Matters’ will shed light on the impact of chronic pain on people's lives and will engage and enlighten viewers," said Camilla Carpenter, senior vice president of business strategy and operations at the Discovery Channel.
A new national survey of 1,255 adults with chronic pain and 505 caregivers found that chronic pain is a daily struggle for nearly all people living with it (94%) and many feel that it burdens their closest relationships with loved ones whom they rely on for daily support (82%). According to the Institute of Medicine, the high prevalence of chronic pain – defined as persistent pain that lasts three months or longer – suggests that the condition is not being adequately managed.
Chronic pain can limit people’s ability to participate in fundamental tasks of daily living. It can also have an impact on a person’s economic, physical and emotional wellbeing. While there are a variety of options available to treat chronic pain, it often cannot be cured, only managed. The goal of pain management is to help the patient improve function and resume day-to-day activities.
The survey results reflect these challenges in pain management. Although most people with pain (69%) experience pain daily, nearly one-third (31%) never or rarely discuss with their healthcare professional whether their treatment plan should be changed. Many people with chronic pain do not often utilize other modalities of pain care like exercise (55%), physical therapy (35%) or psychotherapy (6%), all of which can be important parts of successful pain management.
“The stigma associated with chronic pain can make it hard for people to talk about,” said Penney Cowan, executive director of the American Chronic Pain Association. “I hope that ‘Pain Matters’ and the ‘Individual Burdens of Chronic Pain’ survey help facilitate a conversation of how we can better support people with chronic pain and their loved ones, as the burden from a societal and individual standpoint is substantial .
About “Pain Matters”
“Pain Matters” chronicles the stories of six people with pain and their loved ones: a U.S. Navy veteran who sustained debilitating injuries while serving in Iraq, a two-time Stanley Cup-winning hockey player, a car accident survivor, and individuals with osteoarthritis, fibromyalgia and Complex Regional Pain Syndrome (CRPS). The stories of people with pain are at the center of the film with leading experts in pain management providing perspective on the science behind chronic pain and how it’s treated, the effects of untreated pain, as well as the future of pain management.
“Pain Matters” will air on the Discovery Channel Saturday, Nov. 16, Dec. 7 and Dec. 14 at 8 a.m. It is also available online at www.PainMattersFilm.com. Financial support, clinical input and other expertise for “Pain Matters” were provided by Teva Pharmaceuticals. It was produced by the Discovery Channel in collaboration with seven advocacy organizations, including: American Academy of Pain Management, American Academy of Pain Medicine, American Chronic Pain Association, American Pain Society, American Society for Pain Management Nursing, U.S. Pain Foundation and For Grace.
About the “Individual Burdens of Chronic Pain” Survey
The “Individual Burdens of Chronic Pain” survey was conducted on behalf of Teva Pharmaceuticals in collaboration with the American Chronic Pain Association (ACPA) and the American Academy of Pain Medicine (AAPM). The online national survey included 1,255 adults who have chronic pain and are treated with prescription medication, as well as 505 adults who live in the same household as and care for an adult with chronic pain who is treated with prescription medication.
The American Chronic Pain Association has offered support and information for people with chronic pain since 1980. Its mission is to facilitate peer support and education for individuals with chronic pain and their families so that these individuals may live more fully in spite of their pain, and to raise awareness among the healthcare community, policymakers and the public at large about issues associated with living with chronic pain. Learn more about the American Chronic Pain Association at www.theACPA.org.
The American Academy of Pain Medicine is the premiere medical association for pain physicians and their treatment teams with over 2,400 members. Now in its 29th year of service, the Academy’s mission is to optimize the health of patients in pain and eliminate it as a major public health problem by advancing the practice and specialty of pain medicine through education, training, advocacy and research. More information is available on the Academy’s website at www.painmed.org.
Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) is a leading global pharmaceutical company, committed to increasing access to high-quality healthcare by developing, producing and marketing affordable generic drugs as well as innovative and specialty pharmaceuticals and active pharmaceutical ingredients. Headquartered in Israel, Teva is the world's leading generic drug maker, with a global product portfolio of more than 1,000 molecules and a direct presence in about 60 countries. Teva's branded businesses focus on CNS, oncology, pain, respiratory and women's health therapeutic areas as well as biologics. Teva currently employs approximately 46,000 people around the world and reached $20.3 billion in net revenues in 2012.
Teva's Safe Harbor Statement under the U. S. Private Securities Litigation Reform Act of 1995:
This release contains forward-looking statements, which express the current beliefs and expectations of management. Such statements are based on management’s current beliefs and expectations and involve a number of known and unknown risks and uncertainties that could cause our future results, performance or achievements to differ significantly from the results, performance or achievements expressed or implied by such forward-looking statements. Important factors that could cause or contribute to such differences include risks relating to: our ability to develop and commercialize additional pharmaceutical products, competition for our innovative products, especially Copaxone® (including competition from innovative orally-administered alternatives, as well as from potential purported generic equivalents), competition for our generic products (including from other pharmaceutical companies and as a result of increased governmental pricing pressures), competition for our specialty pharmaceutical businesses, our ability to achieve expected results through our innovative R&D efforts, the effectiveness of our patents and other protections for innovative products, decreasing opportunities to obtain U.S. market exclusivity for significant new generic products, our ability to identify, consummate and successfully integrate acquisitions, the effects of increased leverage as a result of recent acquisitions, the extent to which any manufacturing or quality control problems damage our reputation for high quality production and require costly remediation, our potential exposure to product liability claims to the extent not covered by insurance, increased government scrutiny in both the U.S. and Europe of our agreements with brand companies, potential liability for sales of generic products prior to a final resolution of outstanding patent litigation, our exposure to currency fluctuations and restrictions as well as credit risks, the effects of reforms in healthcare regulation and pharmaceutical pricing and reimbursement, any failures to comply with complex Medicare and Medicaid reporting and payment obligations, governmental investigations into sales and marketing practices (particularly for our specialty pharmaceutical products), uncertainties surrounding the legislative and regulatory pathways for the registration and approval of biotechnology-based products, adverse effects of political or economical instability, corruption, major hostilities or acts of terrorism on our significant worldwide operations, interruptions in our supply chain or problems with our information technology systems that adversely affect our complex manufacturing processes, any failure to retain key personnel or to attract additional executive and managerial talent, the impact of continuing consolidation of our distributors and customers, variations in patent laws that may adversely affect our ability to manufacture our products in the most efficient manner, potentially significant impairments of intangible assets and goodwill, potential increases in tax liabilities, the termination or expiration of governmental programs or tax benefits, environmental risks and other factors that are discussed in our Annual Report on Form 20-F for the year ended December 31, 2012 and in our other filings with the U.S. Securities and Exchange Commission. Forward-looking statements speak only as of the date on which they are made and the Company undertakes no obligation to update or revise any forward-looking statement, whether as a result of new information, future events or otherwise.
# # #
Denise Bradley – 215.591.8974
Nancy Leone – 215.284.0213